GGrantIndex
Sort

40,608 grants matching prostate cancer

High Throughput Microscopy Assays to Identify Inhibitors of Metastasis

$396,325
Sara A Courtneidge · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2010 · CA

High Throughput Microscopy Assays to Identify Inhibitors of Metastasis

$396,325
Sara A Courtneidge · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2009 · CA

The Role of CXCL12 Signaling in Obesity-Induced Prostate Cancer Progression

$396,302
John Digiovanni · University Of Texas At Austin · R01 · FY2017 · CA

The Role of CXCL12 Signaling in Obesity-Induced Prostate Cancer Progression

$396,302
John Digiovanni · University Of Texas At Austin · R01 · FY2018 · CA

The Role of CXCL12 Signaling in Obesity-Induced Prostate Cancer Progression

$396,302
John Digiovanni · University Of Texas At Austin · R01 · FY2016 · CA

Core A: Pathobiology Core

$396,282
Massimo F Loda · Columbia University Health Sciences · P01 · FY2025 · CA

Development of biophysical approaches to investigate high-resolution structure and dynamics of membrane proteins

$396,250
Ayyalusamy Ramamoorthy · Florida State University · R35 · FY2025 · GM

Development of biophysical approaches to investigate high-resolution structure and dynamics of membrane proteins

$396,250
Ayyalusamy Ramamoorthy · Florida State University · R35 · FY2024 · GM

INVESTIGATING THE LONG NONCODING RNA PLUTO-201 AS A DRIVER AND THERAPEUTIC TARGET IN PROSTATE CANCER

$396,250
Regents Of The University Of California, San Francisco, The · · FY2017 · Department of the Army

DEVELOPMENT OF SMALL MOLECULE ACTIVATORS OF PROTEIN PHOSPHOTASE 2A SMAP FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER

$396,250
Case Western Reserve University · · FY2015 · Department of the Army

TARGETING METABOLIC ADAPTATION PATHWAYS TO INHIBIT PROGRESSION AND METASTASIS OF CASTRATION-RESISTANT PROSTATE CANCER

$396,249
Health Research, Inc. · · FY2016 · Department of the Army

Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending

$396,240
Brent K. Hollenbeck · University Of Michigan At Ann Arbor · R01 · FY2017 · HS

CANCER SERO EPIDEMIOLOGY AMONG THE JAPANESE IN HAWAII

$396,237
Kuakini Medical Center · R01 · FY2002 · CA

Daily Quantification of Cancer-Associated Exosomal miRNA in Patient Blood by Photonic Crystal-Enhanced Quantum Dot Emission

$396,237
Andrew Michael Smith · University Of Illinois At Urbana-Champaign · R01 · FY2018 · CA

CLINICAL TRIAL: THE SELENIUM AND VITAMIN E CHEMOPREVENTION TRIAL (SELECT)

$396,181
Rowan A Chlebowski · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · M01 · FY2008 · RR

Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer

$396,130
Ming Hui Chen · Duke University · R01 · FY2025 · CA

Molecular Mechanisms of Polyoma Induced Transformation

$396,128
Thomas M Roberts · Dana-Farber Cancer Inst · R01 · FY2010 · CA

ANTITUMOR MECHANISMS &THERAPEUTIC EFFECTS OF VITAMIN D

$396,101
University Of Pittsburgh At Pittsburgh · R01 · FY2001 · CA

Cancer Care and Outcomes for Disabled Medicare Patients

$396,092
Beth Israel Deaconess Medical Center · R01 · FY2005 · CA

Prospective Studies of Diet and Cancer in Men and Women

$396,040
Walter C. Willett · Harvard School Of Public Health · P01 · FY2009 · CA

Understanding Resistance to Next Generation Antiandrogens

$396,018
Charles L Sawyers · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA

Chlorotoxin as a Targeting Agent for Cancer Therapies

$396,000
James M Olson · Fred Hutchinson Cancer Research Center · R01 · FY2015 · CA

Chlorotoxin as a Targeting Agent for Cancer Therapies

$396,000
James M Olson · Fred Hutchinson Cancer Research Center · R01 · FY2014 · CA

OPTIMIZING TREATMENT OF ADVANCED PROSTATE CANCER AND EXPLOITING MECHANISMS DRIVING CASTRATION RESISTANCE

$396,000
Fred Hutchinson Cancer Research Center · · FY2010 · Department of the Army

Chlorotoxin as a Targeting Agent for Cancer Therapies

$396,000
James M Olson · Fred Hutchinson Cancer Research Center · R01 · FY2017 · CA